

Bridge HIV: Research Overview

Innovations in HIV Prevention

Health Commission Community and Public Health Committee
November 16, 2021

Susan Buchbinder, MD, Director

Albert Liu, MD MPH, Clinical Research Director

Hyman Scott, MD MPH, Medical Director of Clinical Research



Who we are?



NIH-funded Clinical Trials Unit which operates within the San Francisco Department of Public Health and is affiliated with UCSF

Bridge HIV Mission

To collaborate with communities in conducting innovative research that will guide HIV prevention locally and globally.



Bridge HIV: A Tradition of Innovative Research to Prevent HIV/AIDS



COVID-19
Prevention Network

*Active studies



HIV VACCINE
TRIALS NETWORK

HIV Vaccines
bNAbs



HPTN
HIV Prevention
Trials Network

Novel PrEP agents
Long acting PrEP formulations
Integrated Strategies




PrEP support tools




COVID-19 Prevention Network (CoVPN)

- **Formed by NIH**
 - Global network of NIH sites and Clinical Research Organization sites, as needed
 - Links together multiple NIH-sponsored networks
 - Local sites include Bridge HIV (SFDPH), UCSF/ZSFG, EBAC (Oakland), SFVAH
- **Mission: To conduct Phase III efficacy trials to prevent infection and COVID-19 disease (Moderna, AZ, J&J, Novavax, Sanofi)**
- **We enrolled 256 participants in the AZ trial**
 - 32% Latinx, 20% Black/African American, 20% Asian, 19% White, 13% Asian, 2% Native Hawaiian/Pacific Islander; 1% American Indian/Alaskan Native
 - 30% over 60 yo



Community Engagement is Key

BRIDGE HIV in partnership with
HOUSE OF MIZRAHI, HOUSE OF ENERGI,
HOUSE OF PROLIFIC, & HOUSE OF INFINITI
proudly presents



PrEP & Vogue

NOVEMBER 16, 2016
6 PM / BETTI ONO GALLERY
OAKLAND / CA

➤ FREE EVENT & DINNER



Full Circle

FROM VAGINAL RINGS TO SEXUAL SAFETY

A BRIDGE HIV COMMUNITY FORUM / COMMEMORATING 

A BRIDGE HIV COMMUNITY FORUM

PREVENT AND PROTECH
THE INTERSECTION BETWEEN HIV RESEARCH & TECHNOLOGY

COME LEARN ABOUT HOW DIGITAL HEALTH IS IMPROVING HEALTH DISPARITIES IN THE FIELD OF HIV PREVENTION.

TUESDAY
APRIL 24
2018 6-8 PM

CITY COLLEGE OF SAN FRANCISCO
MULTI-USE BUILDING (MUB 140)
50 PHELAN AVENUE / SF

REGISTER AT
PREVENTANDPROTECH.EVENTBRITE.COM

FREE ADMISSION / PUPUSAS / RAFFLE
CEU'S AVAILABLE FOR ALL NURSING LICENSES

BridgeHIV CITY COLLEGE OF SAN FRANCISCO

ADA ACCESSIBLE

TRANS*COVID

A CONVERSATION TO ADDRESS THE TRANS COMMUNITY'S CONCERNS & TRANSCEND BEYOND THE COVID-19 PANDEMIC.

4PM / SATURDAY
MAY 16, 2020

JOIN US ON ZOOM TO HELP EMPOWER OUR COMMUNITY & PROMOTE SELF ADVOCACY:
TRANSCOVID.EVENTBRITE.COM

LOTUS DÓ, LCSW
HE/HIM THEY/THEM


KRISTINA JA'LYXIE BLIOUX, CPT1
SHE/HER/HERS

NENNA JOINER
FEELMORE510.COM
THEY/THEM

LAURYN TERRY, RN
SHE/HER/HERS


STAY BridgeHIV

San Francisco City Clinic: % of MSM on PrEP at their SFCC visit, by race/ethnicity



PrEP uptake increasing each year in all racial/ethnic groups at SFCC, but disparities remain, particularly for Black/African American MSM

Lack of PrEP persistence accentuates disparities



PrEP discontinuation rates high

- Average duration: 8.3 mo
- Retention at 12 mo: 38%
- Higher discontinuation:
 - Youth
 - African American
 - PWID
 - Transwomen

LYNX: Mobile app to increase HIV testing and PrEP uptake (ATN 140 and ATN 143)




Welcome to Lynx!

Lynx is all about blending pleasure with HIV prevention. It'll help you track, check, and protect so you can focus on the pleasure of sex.



NEXT

SMS Support for PrEP Retention & Adherence



- Two-way texting support tool, developed by SFDPH with WeTel
- Shown to double PrEP persistence in young, diverse MSM
- First CDC-adopted Evidence-Based Intervention for PrEP

Liu CID 2018; Lester Lancet 2010; Chiang JMIR mHealth & uHealth 2018



How is PrEP going?

Ok

Not great.

PI Liu, R01 MH095628

Adherence Tracking and Protection Levels

Sketch 9:41 AM 100%

DOT DIARY

Today Month Summary

S	M	T	W	T	F	S
6	7	8	9	10	11	12

TODAY PROTECTION LEVEL

No/Low

Take PrEP for 3 days to be highly protected.

Add new encounter

Dashboard Take Dose

Sketch 9:41 AM 100%

DOT DIARY

Today Month Summary

S	M	T	W	T	F	S
6	7	8	9	10	11	12

TODAY PROTECTION LEVEL

Medium

Take PrEP for 2 days to be highly protected.

Add new encounter

Dashboard Take Dose

Sketch 9:41 AM 100%

DOT DIARY

Today Month Summary

S	M	T	W	T	F	S
6	7	8	9	10	11	12

TODAY PROTECTION LEVEL

High

Continue taking PrEP daily.

Add new encounter

Dashboard Take Dose

Digital Support for PREP 2-1-1

PI Liu, R34 MH121139

Home screen with timer

PrEPmate 211

TODAY MONTH

M T W T F S S

Dosing 2

Sex ☆

Last Dose
June 17 2018
9 am

Time to protection:
1h: 19min.

Home PrEP Diary Trends Chat

Home screen

PrEPmate 211

TODAY MONTH

M T W T F S S

Dosing 2 1 1

Sex ☆ ☆ ☆

TODAY
June 19, 2018

Your next dose is tomorrow at
9 am

Your last dose was 1 day ago

Protection level:
HIGH

Home PrEP Diary Trends Chat

Legend

PrEPmate 211

Key

- ☆ Confirmed sex day
- ☆ Possible sex day

Protection Level

- High protection
- Medium protection
- Low/no protection

Home PrEP Diary Trends Chat

Trends

PrEPmate 211

6 # of sex days last month

% of time sex acts occur by day of week:

M	T	W	T	F	S	S
0%	0%	20%	0%	60%	20%	0%

40% of all sex acts covered by PrEP

Having trouble with 211 PrEP? Chat with your provider about switching to daily PrEP.

Sex acts covered by PrEP

PRE/POST PrEP TAKEN	ONLY PRE PrEP TAKEN	ONLY POST PrEP TAKEN	NONE TAKEN
40%	20%	20%	20%

Home PrEP Diary Trends Chat


PrEP-3D: Digital Diary and Delivery for MSM





- Pharmacy-led models of PrEP delivery are feasible and sustainable can reduce burden on clinics^{1,2}

- PrEP-3D

- Online pharmacist provides PrEP Rx, orders/tracks lab monitoring through collaborative practice agreement
- Medication delivery through courier
- Online tools (pill/sex diary, bi-directional messaging) support adherence and persistence



Buchbinder R01 MH119956-01



¹Tung E National HIV Prevention Conference Atlanta 2015; ²Marcus Current HIV/AIDS Reports 2016, Lopez J Am Pharm Assoc 2019

Studies underway or on the horizon

- Merck
 - New monthly PrEP pill for MSM/TGW
- Gilead
 - New semi-annual injectable PrEP for TGW
- GSK
 - Study of genital herpes outbreaks
 - Possible study of the meningococcal vaccine to prevent gonorrhea
- AMBER
 - Socio-behavioral research to guide PrEP implant development in MSM, cisgender women, and TGW
- PrEP and ART implementation
 - PCORI: Comparative effectiveness trial evaluating 2 mobile technologies to support PrEP use
 - Viiv: Novel delivery model for injectable ART treatment for transwomen
 - HOPE: Mobile clinic delivery of HIV status neutral services to the African American community
- HIV Vaccines and monoclonal antibodies
 - Mosaico: HIV vaccine efficacy trial (fully enrolled)
 - Four Phase 1 or 2 studies of new vaccine or monoclonal antibodies for HIV prevention

Thank you!

HELP **FI**IGHT HIV **.ORG**

BridgeHIV™

San Francisco Department of Public Health

